Clinical trial
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant…
NCT00293124 · Central European Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00293124 |
|---|---|
| Title | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors |
| Official title | An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit. |
| Lead sponsor | Central European Cooperative Oncology Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Glivec |
| Enrollment | 125 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Feb 17, 2006 |
| Last update posted | Aug 13, 2015 |
| Countries | Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Lithuania, Romania, Serbia, Slovakia, Slovenia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: